Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases
- PMID: 3297620
- DOI: 10.2165/00003495-198733050-00002
Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases
Abstract
Buflomedil hydrochloride is a vasoactive drug with a variety of pharmacodynamic properties. Importantly, it seems to improve nutritional blood flow in ischaemic tissue of patients with peripheral and/or cerebral vascular disease by a combination of pharmacological effects: inhibition of alpha-adrenoceptors, inhibition of platelet aggregation, improved erythrocyte deformability, nonspecific and weak calcium antagonistic effects, and oxygen sparing activity. Therapeutic trials with buflomedil in patients with peripheral vascular diseases have shown that it increases walking distances in those with intermittent claudication and heals trophic lesions and reduces rest pain in many patients with more severe vasculopathies. In open clinical trials a good to very good clinical response was achieved in 57 to 87% of those treated. In comparative studies buflomedil 600 mg/day orally was shown to be significantly superior to placebo and comparable in efficacy to pentoxifylline (oxpentifylline) and naftidrofuryl. In patients with symptoms presumed to be due to cerebrovascular insufficiencies and elderly patients with senile dementia, buflomedil 450 to 600 mg/day alleviated symptoms associated with impairment of cognitive and psychometric function and was significantly superior to placebo and slightly more effective than drugs such as cinnarizine, flunarizine and co-dergocrine mesylate. Overall, buflomedil at dosages of up to 600 mg/day has been very well tolerated and discontinuation of therapy has rarely been necessary. Thus, buflomedil would seem to be a useful adjunct to conservative treatment in patients with mild-to-moderate peripheral vascular disease and/or cerebrovascular insufficiency, and well worth a try in patients with more severe peripheral disease unable to undergo surgery. However, a few well-designed long term studies are needed to fully define its overall place in therapy.
Similar articles
-
An experimental overview of a new vasoactive drug: buflomedil HCl.Angiology. 1981 Oct;32(10):663-75. doi: 10.1177/000331978103201001. Angiology. 1981. PMID: 7034590 Review.
-
Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication.Int Angiol. 2001 Dec;20(4):337-44. Int Angiol. 2001. PMID: 11782701 Clinical Trial.
-
Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders.Drugs Aging. 1995 Dec;7(6):480-503. doi: 10.2165/00002512-199507060-00007. Drugs Aging. 1995. PMID: 8601054 Review.
-
The treatment of senile dementia associated with cerebrovascular insufficiency: a comparative study of buflomedil and dihydrogenated ergot alkaloids.J Int Med Res. 1985;13(1):48-53. doi: 10.1177/030006058501300107. J Int Med Res. 1985. PMID: 3884411 Clinical Trial.
-
Multicentre clinical placebo-controlled study with buflomedil in the treatment of mild dementia of vascular origin.J Int Med Res. 1992 Apr;20(2):136-49. doi: 10.1177/030006059202000206. J Int Med Res. 1992. PMID: 1521670 Clinical Trial.
Cited by
-
Effects of buflomedil and pentoxifylline on hamster skin-flap microcirculation: prediction of flap viability using orthogonal polarization spectral imaging.Clinics (Sao Paulo). 2009;64(8):797-802. doi: 10.1590/S1807-59322009000800015. Clinics (Sao Paulo). 2009. PMID: 19690666 Free PMC article.
-
Drugs that alter blood viscosity. Their role in therapy.Drugs. 1990 Feb;39(2):155-9. doi: 10.2165/00003495-199039020-00001. Drugs. 1990. PMID: 2183997 Review. No abstract available.
-
Effects of torbafylline, pentoxifylline and buflomedil on vascularisation and fibre type of rat skeletal muscles subjected to limited blood supply.Br J Pharmacol. 1990 Apr;99(4):786-90. doi: 10.1111/j.1476-5381.1990.tb13007.x. Br J Pharmacol. 1990. PMID: 2361174 Free PMC article.
-
Separation of pyrrolidine from tetrahydrofuran by using pillar[6]arene-based nonporous adaptive crystals.Chem Sci. 2022 Jun 2;13(25):7536-7540. doi: 10.1039/d2sc02494b. eCollection 2022 Jun 29. Chem Sci. 2022. PMID: 35872814 Free PMC article.
-
Buflomedil poisoning: five cases with cardiotoxicity.Intensive Care Med. 1996 Jan;22(1):57-61. doi: 10.1007/BF01728332. Intensive Care Med. 1996. PMID: 8857439
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical